Stoke Therapeutics, Inc. (STOK): Shareholders' Equity
$352.46M
As of 2025-12-31
$345.55M
As of 2026-06-30
+24.0%
3-year compound annual growth
+4.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $352.46M | +53.9% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $229.02M | +43.5% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $159.56M | -13.7% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $184.85M | -15.1% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $217.78M | -23.9% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $286.08M | +27.5% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $224.43M | +113.6% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $105.07M | n/a | 2020-03-23, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $352.46M | +53.9% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $212.38M | -34.7% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $33.59M | -3.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $502.64M | +25.1% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$438.17M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $459.28M | -5.5% |
| Liquidia Corp (LQDA) | 2025-12-31 | $44.75M | -43.6% |
Compare STOK, MRVI, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗